Nuclear inhibitor I-92 and its use for the production of a medic

Details Nuclear inhibitor I-92 and its use for the production of a medic Nuclear inhibitor I-92 and its use for the production of a medic

1994-01-19

2000-04-04

Achutamurthy, Ponnathapura

Drug, bio-affecting and body treating compositions

Extract, body fluid, or cellular material of undetermined...

435325, 435366, 435367, 436501, 530300, 530350, 530358, 530412, A61K 3512

Patent

active

060458313

ABSTRACT:
The present invention concerns a nuclear inhibitor which specifically inhibits the activity of sequence specific DNA enhancer binding proteins of Human Papilloma Virus (HPV) and the use of this nuclear inhibitor for the production of a medicament for treatment of human cervical cancer.

REFERENCES:
Weitz, J., et al., "A Novel Nuclear Inhibitor I-92 Regulates DNA Binding Activity of Octamer Binding Protein p92 During the Cell Cycle," Nucleic Acids Res, vol. 19, No. 20, p. 5725-30, Oct. 25, 1991.
Delineation of Human Papillomavirus Type 18 Enhancer Binding Proteins: The Intracellular Distribution of a Novel Octamer Binding Protein p92 is Cell Cycle Regulated, Royer et al., Nucleic Acids Research, 19(9):2363-2371 (1991).
Characterization of a Cell Type-Specific Enhancer Found in The Human Papilloma Virus Type 18 Genome, Swift et al., The EMBO Journal, 6(5):1339-1344 (1987).
At Least Two Nuclear Proteins Bind Specifically to The Rous Sarcoma Virus Long Terminal Repeat Enhancer, Sealey et al., Molecular and Cellular Biology, 7(2)-787-798 (1987).
Transcriptional Regulation Of The Human Papillomavirus-16 E6-E7 Promoter By A Keratinocyte-Dependent Enhancer, And By Viral E2 Trans-Activator And Repressor Gene Products: Implications For Cervical Carcinogenesis, Cripe et al., The EMBO Journal, 6(12):3745-3753 (1987).
Human Papillomaviruses and Cervical Carcinoma, Vousden, Cancer Cells, 1(2):43-50 (1989).
In Situ Detection of Sequence-Specific DNA Binding Activity Specified By A Recombinant Bacteriophage, Vinson et al., Genes and Development, 2:801-806 (1988).
A Two-Base Change in a POU Factor-Binding Site Switches Pituitary-Specific to Lymphoid-Specific Gene Expression, Elsholtz et al., Genes & Development 4:43-51 (1990).
Transcriptional Activation of the human Papillomavirus-16 P97 Promoter by an 88-Nucleotide Enhancer Containing Distinct Cell-Dependent And AP-1 Responsive Modules, Cripe et al., The New Biologist, 2(5):450-463 (1990).
Expression of a Large Family of POU-Domain Regulatory Genes in Mammalian Brain Development, X. He et al., Nature, 340:35-42 (1989).
Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4, U.K. Laemmli, Nature, 227:680-685 (1970).
Correlation of Modified Human Papilloma Virus Early Gene Expression With Altered Growth Properties in C4-1 Cervical Carcinoma Cells, Doeberitz et al Cancer Research, 48:3780-3786 (1988).
Continued Expression of HPV-16 E7 Protein is Required for Maintenance of the Transformed Phenotype of Cells Co-Transformed by HPV-16 Plus EJ-ras, Crook et al., The EMBO Journal, 8(2):513-519 (1989).
The Retinoblastoma Susceptibility Gene Product Undergoes Cell Cycle-Dependent Dephosphorylation and Binding to and Release From SV40 Large T, Ludlow et al., Cell, 60:387-396 (1990).
Inducible and Constitutive Enhancer Domains in the Noncoding Region of Human Papillomavirus Type 18, Gius et al., Journal of Virology, 62(3):665-672 (1988).
I.kappa.B: A Specific Inhibitor of the NF-.kappa.B Transcription Factor, Baeuerle et al Science, 242:540-546 (1988).
Human Cell Hybrids: Analysis of Transformation and Tumorigenicity, Stanbridge et al., Science, 215:252-259 (1982).
Numerous Nuclear Proteins Bind the Long Control Region of Human Papillomavirus Type 16: A Subset of 6 of 23 DNase I-Protected Segments Coincides With the Location of the Cell-Type-Specific Enhancer, Gloss et al Journal of Virology, 63(3):1142-1152 (1989).
Interplay of Viral and Cellular Proteins Along the Long Control Region of Human Papillomavirus Type 18, Garcia-Carranca et al., Journal of Virology, 62(11):4321-4330 (1988).
Characterization of a Transcriptional Promoter of Human Papillomavirus 18 and Modulation of Its Expression by Simian Virus 40 and Adenovirus Early Antigens, Thierry et al., Journal of Virology, 61(1):134-142 (1987).
Octamer Transcription Factors Bind to Two Different Sequence Motifs of the Immunoglobulin Heavy Chain Promoter, Kemler et al., The EMBO Journal, 8(7):2001-2008 (1989).
Eukaryotic Transcriptional Regulatory Proteins, Johnson et al., Annu. Rev. Biochem., 58:799-839 (1989).
Structure and Transcription of Human Papillomavirus Sequences in Cervical Carcinoma Cells, Schwarz et al., Nature, 314:111-114 (1985).
Clusters of Nuclear Factor 1 Binding Sites Identify Enhancers of Several Papillomaviruses But Alone Are Not Sufficient For Enhancer Function, Gloss et al., Nucleic Acids Research, 17(9):3519-3533 (1989).
Transcriptionial Activation of Human Papillomavirus 16 by Nuclear Factor 1, AP1, Steroid Receptors and a Possibly Novel Transcription factor, PVF: a Model for the Composition of Genital Papillomavirus Enhancers, Chong et al. Nucleic Acids Research, 18(3):465-470 (1990).
A Cloned Octamer Transcription Factor Stimulates Transcription From Lymphoid-specific Promoters in Non-B Cells, Muller et al., Nature, 336:544-551 (1988).
Transcription Factor AP-2 Mediates Induction By Two Different Transduction Pathways: Protein Kinase C and cAMP, Cell, 51:251-260 (1987).
DNA Binding Proteins Present in Guanidinium Isothiocyanate Lysates of Cells Are Suitable for Specific Binding Site Blotting, Nucleic Acids Research, 17(21):8891 (1989).
A Nuclear Factor That Binds to a Conserved Sequence Motif in Transcriptional Control Elements of Immunoglobulin Genes, Nature, 319:154-158 (1986).
Identification of a Novel Constitutive Enhancer Element and an Associated Binding Protein: Implications for Human Papillomavirus Type II Enhancer Regulation, Chin et al., Journal of Virology, 63(7):2967-2976 (1989).
A Novel Nuclear Inhibitor I-92 Regulates DNA Binding Activity of Octamer Binding Protein P92 During The Cell Cycle, J. Weitz et al., Nucleic Acids Acids Research, 19(20):5725-5730 (1991).

Affiliated with

Also associated with

Rating

Nuclear inhibitor I-92 and its use for the production of a medic does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nuclear inhibitor I-92 and its use for the production of a medic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nuclear inhibitor I-92 and its use for the production of a medic will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-362558